Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer
42nd Annual Chemotherapy Foundation Symposium
Vered Stearns, MD, is the Director for Translational Breast Cancer Research in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer Center and Weill Cornell Medical School. Dr. Stearns talks about updates in the management of patients with triple-negative breast cancer. Triple-negative breast cancer affects a small portion of all breast cancer subtypes, representing about 15% of tumors. It is more common in younger women, in black African American women, and those who are BRCA mutation carriers. Dr. Stearns shares her expertise on the management of patients with triple-negative breast cancer and some of the advances made in treatment.
The ASCO Post Staff
Komal Jhaveri, MD, FACP, is an Associate Professor of Clinical Medicine at Weill Cornell Medical College and a Breast Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center in New York. In this video from The ASCO Post Newreels, Dr. Jhaveri shares a summary of her talk presented recently at the Chemotherapy Foundation Symposium. Dr. Jhaveri discusses important data about the activity of antibody-drug conjugates in patients with breast cancer, including breast cancer that is HER2-positive, HER2-low, and HER2-ultralow.
The ASCO Post Staff
Tiffany Traina, MD, FASCO, is Vice Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center, where she has been a medical oncologist on the Breast Medicine Service since 2006. Dr. Traina is also the Section Head of the Triple Negative Breast Cancer Clinical Research Program. In this video, Dr. Traina speaks with The ASCO Post about management options and advances in the treatment of HR-positive breast cancer. Dr. Traina was co-Program Chair of the recent Chemotherapy Foundation Symposium.
